Get the Stockscreener App
13.50
1.12%
0.15
After Hours:
13.49
-0.010
-0.07%
Maze Therapeutics Inc stock is traded at $13.50, with a volume of 136.55K.
It is up +1.12% in the last 24 hours and down -15.68% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$13.35
Open:
$13.42
24h Volume:
136.55K
Relative Volume:
1.13
Market Cap:
$591.26M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.74%
1M Performance:
-15.68%
6M Performance:
+12.50%
1Y Performance:
+0.00%
1-Day Range:
$12.86
$13.58
1-Week Range:
$12.86
$14.56
52-Week Range:
$6.71
$18.67
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
13.50 | 584.69M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
Is it time to cut losses on Maze Therapeutics Inc.July 2025 Momentum & Risk Controlled Swing Trade Alerts - Newser
Risk adjusted return profile for Maze Therapeutics Inc. analyzed2025 Sector Review & Consistent Profit Trading Strategies - Newser
Will a bounce in Maze Therapeutics Inc. offer an exitBond Market & Fast Gain Swing Trade Alerts - Newser
How Maze Therapeutics Inc. stock performs during market volatility2025 Trading Volume Trends & High Accuracy Trade Signal Alerts - newsyoung.net
Maze Therapeutics: Promising Future with Strong Pipeline and Robust Financial Health - TipRanks
Maze Therapeutics Plunges 17.08% Despite Beating EPS Estimates - AInvest
Why Maze Therapeutics Inc. stock attracts strong analyst attentionPortfolio Risk Report & Real-Time Volume Spike Alerts - Newser
Should you wait for a breakout in Maze Therapeutics Inc.Quarterly Portfolio Report & Entry and Exit Point Strategies - Newser
RSI Divergence May Trigger a Bounce in Maze Therapeutics Inc.July 2025 Levels & Expert Curated Trade Setups - newsyoung.net
Institutional scanner results for Maze Therapeutics Inc.Gap Up & High Accuracy Investment Signals - Newser
Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15) - MSN
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials - TipRanks
What’s the recovery path for long term holders of Maze Therapeutics Inc.Quarterly Portfolio Summary & Weekly High Return Stock Opportunities - Newser
Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782 - TipRanks
Using data models to predict Maze Therapeutics Inc. stock movement - Newser
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - GlobeNewswire
How to escape a deep drawdown in Maze Therapeutics Inc.Free Real Market Momentum Signal Generator - Newser
Will Maze Therapeutics Inc. stock recover after earningsExploding Volume High ROI Picks - newsyoung.net
When is the best time to exit Maze Therapeutics Inc.Technical Chart Summary for Momentum Stocks - Newser
Published on: 2025-08-12 08:41:52 - Newser
What moving averages say about Maze Therapeutics Inc.Profit Target Planning with Exit Confidence - Newser
How to build a custom watchlist for Maze Therapeutics Inc.Real Market Tracker with Price Action Tools - Newser
What makes Maze Therapeutics Inc. stock price move sharplyStock Entry Point Planner with Volume Spike - Newser
Visual trend scoring systems applied to Maze Therapeutics Inc.Portfolio Risk Distribution Analysis Tool - Newser
Real time pattern detection on Maze Therapeutics Inc. stockFree Risk-Adjusted Picks With Exit Strategy - Newser
Bank of New York Mellon Corp Makes New Investment in Maze Therapeutics, Inc. (NASDAQ:MAZE) - Defense World
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $25.60 Average Price Target from Analysts - Defense World
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):